Atea Pharmaceuticals (AVIR) Operating Expenses (2019 - 2026)

Atea Pharmaceuticals' Operating Expenses history runs 8 years deep, the most recent figure standing at $48.0 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 22.97% year-over-year to $48.0 million in Q1 2026; TTM through Mar 2026 was $189.9 million, a 17.06% increase from a year earlier, with the FY2025 full-year figure at $180.9 million, down 6.25% from the prior year.
• Operating Expenses fell to $48.0 million in Q1 2026 per AVIR's latest filing, from $54.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $69.8 million in Q1 2024 and bottomed at $16.3 million in Q3 2022.
• The 5-year median for Operating Expenses is $41.3 million (2025), against an average of $42.2 million.
• Across the five-year window, Operating Expenses slumped 70.38% in 2022 and surged 150.51% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $39.9 million in 2022, then rose by 16.73% to $46.6 million in 2023, then declined by 16.2% to $39.0 million in 2024, then jumped by 40.76% to $54.9 million in 2025, then retreated by 12.61% to $48.0 million in 2026.
• Per Business Quant, the three latest AVIR Operating Expenses figures stand at $48.0 million (Q1 2026), $54.9 million (Q4 2025), and $45.6 million (Q3 2025).